	US 12,458,619 B2
	Terpene-enriched cannabinoid composition for treatment of male subjects
Noa Raz, Gizo (IL); Aharon Eyal, Jerusalem (IL); and Carmi Raz, Gizo (IL)
Filed by BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD., Or Akiva (IL)
Filed on Jan. 8, 2021, as Appl. No. 17/144,171.
Application 17/144,171 is a continuation in part of application No. PCT/IB2019/055772, filed on Jul. 7, 2019.
Claims priority of provisional application 62/695,056, filed on Jul. 8, 2018.
Prior Publication US 2021/0128522 A1, May 6, 2021
Int. Cl. A61K 31/352 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/01 (2006.01); A61K 31/015 (2006.01); A61K 31/045 (2006.01); A61K 31/05 (2006.01); A61K 31/125 (2006.01); A61K 31/202 (2006.01); A61K 31/353 (2006.01); A61K 33/30 (2006.01); A61K 36/185 (2006.01); A61K 36/19 (2006.01); A61K 36/258 (2006.01); A61K 36/31 (2006.01); A61K 36/46 (2006.01); A61K 36/53 (2006.01); A61K 36/889 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61K 47/46 (2006.01); A61P 13/08 (2006.01); A61P 15/10 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/26 (2006.01); A61P 25/28 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 9/006 (2013.01); A61K 9/007 (2013.01); A61K 9/0078 (2013.01); A61K 9/20 (2013.01); A61K 31/01 (2013.01); A61K 31/015 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/125 (2013.01); A61K 31/202 (2013.01); A61K 31/353 (2013.01); A61K 33/30 (2013.01); A61K 36/185 (2013.01); A61K 36/19 (2013.01); A61K 36/258 (2013.01); A61K 36/31 (2013.01); A61K 36/46 (2013.01); A61K 36/53 (2013.01); A61K 36/889 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61K 47/46 (2013.01); A61P 13/08 (2018.01); A61P 15/10 (2018.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); A61P 25/26 (2018.01); A61P 25/28 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01)]

1 Claim

1. A method for treating a condition selected from the group consisting of androgen deficiency, infertility, urogenital or reproductive system infections and/or disorders and combinations thereof in a male subject diagnosed as suffering from said condition, the method comprising administering to the male subject a therapeutically effective amount of a composition comprising

(i) at least one cannabinoid at a total concentration of at least 5% by weight, wherein said at least one cannabinoid comprises tetrahydrocannabinol (THC), and wherein at least 50% of said at least one cannabinoid is in decarboxylated form,

(ii) at least two terpenes selected from the group consisting of thujone, pinene, limonene, cymene, caryophyllene, caryophyllene oxide, eucalyptol, terpineol, sabinene, carene, geraniol, camphor and citronellol at a total concentration of at least 0.5% by weight, and

(iii) at least 5% by weight of a non-cannabinoid, non-terpene carrier,

wherein the composition is provided in a delivery form selected from the group consisting of tablets, gel capsules, sublingual oils, edibles, cigarettes, vaporizer liquids, nasal preparations, and combinations thereof, and

wherein a total amount of terpenes to a total amount of cannabinoids in said composition is from about 0.1:1 to about 0.5:1, and

wherein said composition is produced by adding at least one isolated terpene to a cannabis extract.